Bullet Bio has worked with big pharma and academic partners to develop a wide variety of immunotherapy products, and we would welcome the chance to work with you. All applications leverage the same Bullet Capsid, customized with different attachments. The products created are novel products eligible for composition-of-matter patent protection. Our primary interest in is immuno-oncology applications:

Intratumoral Vaccines

Bullet Bio has generated positive efficacy data on intratumoral vaccines in multiple preclinical studies.

Multi-specific Antibodies

Antibodies conjugated to Bullet Capsids can get T cells to engage and kill cancer cells. 

Antigen Vaccines

By combining different antigens and immune stimulants on the Bullet Capsid we can create tumor-specific immune responses.